EVOLUTION OF CANCER TREATMENT: TARGETED THERAPIES AND IMMUNOTHERAPY

Abstract

Cancer treatment has undergone a notable evolution with the introduction of targeted therapies and immunotherapy. These innovative approaches have revolutionized the way we tackle this complex and challenging disease. Targeted therapies consist of targeting specific molecules involved in the growth and survival of cancer cells, while immunotherapy aims to stimulate the patient's immune system to recognize and attack cancer cells. The immunotherapy revolution has brought to light a new treatment paradigm, where the immune system itself is exploited to fight cancer. Immune checkpoint inhibitors, such as anti-PD-1 and anti-PD-L1 antibodies, have shown promising results in several types of cancer, providing long-lasting remissions in some patients. Additionally, targeted therapies have demonstrated efficacy in cancers with specific mutations, allowing for more precise and personalized treatment. The combination of targeted therapies and immunotherapy has shown promise, enhancing the positive effects of both approaches and increasing response rates in patients. Scientific and technological advances have allowed the development of predictive biomarkers, helping to identify the patients most likely to respond to these therapies. Despite notable advances, we still face considerable challenges, such as resistance to treatment, variability in patient response and associated costs. Ongoing research and multidisciplinary collaboration are key to overcoming these challenges and further improving existing therapies. As we look to the future, it is exciting to consider the promising prospects that targeted therapies and immunotherapy offer in the treatment of cancer. With continued progress in understanding the molecular and immunologic underpinnings of cancer, we are getting closer to providing more effective and personalized treatment options for patients, bringing renewed hope to those affected by this devastating disease.